{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:33:11Z","timestamp":1792359191600,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic heart failure is one of the most common causes of hospitalization and death in industrialized countries. Demographic changes with an aging population are expected to further increase the prevalence of chronic heart failure. The associated increase in comorbidities in patients with chronic heart failure leads to a\u00a0less favorable prognosis for survival. A\u00a0selection of the major comorbidities discussed in this review\u2014along with prevalence, impact on prognosis, treatment approaches, and current study status\u2014include atrial fibrillation, arterial hypertension, coronary artery disease, coronary microvascular dysfunction, renal dysfunction, type\u00a02\u00a0diabetes, sleep apnea, reduced lymphatic reserve, and the effects on oxygen utilization and physical activity. The complex clinical picture of heart failure with preserved ejection fraction (HFpEF) remains challenging in the nearly absence of evidence-based therapy. Except for comorbidity-specific guidelines, no HFpEF-specific treatment of comorbidities can be recommended at this time. Optimized care is becoming increasingly relevant to reducing hospitalizations through a\u00a0seamless inpatient and outpatient care structure. Current treatment is focused on symptom relief and management of associated comorbidities. Therefore, prevention through early minimization of risk factors currently remains the best approach.<\/jats:p>","DOI":"10.1007\/s00059-022-05123-9","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T07:14:31Z","timestamp":1654672471000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Comorbidities in heart failure with preserved ejection fraction","Komorbidit\u00e4ten bei Herzinsuffizienz mit erhaltener Ejektionsfraktion"],"prefix":"10.1007","volume":"47","author":[{"given":"Andrea","family":"Deichl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"5123_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.amjcard.2020.11.039","volume":"142","author":"OM Aldaas","year":"2021","unstructured":"Aldaas\u00a0OM et al (2021) Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. Am J Cardiol 142:66\u201373","journal-title":"Am J Cardiol"},{"issue":"16","key":"5123_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD et\u00a0al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N\u00a0Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"2","key":"5123_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jchf.2015.09.014","volume":"4","author":"M Arzt","year":"2016","unstructured":"Arzt\u00a0M et al (2016) Prevalence and predictors of sleep-disordered breathing in patients with stable chronic heart failure: the SchlaHF registry. JACC Heart Fail 4(2):116\u2013125","journal-title":"JACC Heart Fail"},{"key":"5123_CR4","unstructured":"AstraZeneca (2022) FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction. https:\/\/www.astrazeneca-us.com\/content\/az-us\/media\/press-releases\/2022\/farxiga-met-primary-endpoint-in-deliver-phase-III-trial.html. Accessed 5 May 2022"},{"issue":"10","key":"5123_CR5","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin\u00a0EJ et al (2019) Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 139(10):e56\u2013e528","journal-title":"Circulation"},{"issue":"3","key":"5123_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/CIRCHEARTFAILURE.114.001915","volume":"8","author":"BA Borlaug","year":"2015","unstructured":"Borlaug\u00a0BA et\u00a0al (2015) Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail 8(3):533\u2013541","journal-title":"Circ Heart Fail"},{"key":"5123_CR7","doi-asserted-by":"publisher","first-page":"d4169","DOI":"10.1136\/bmj.d4169","volume":"343","author":"R Boussageon","year":"2011","unstructured":"Boussageon\u00a0R et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169","journal-title":"BMJ"},{"issue":"1","key":"5123_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland\u00a0JGF et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart\u00a0J 39(1):26\u201335","journal-title":"Eur Heart J"},{"issue":"2","key":"5123_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","volume":"14","author":"VM Conraads","year":"2012","unstructured":"Conraads\u00a0VM et al (2012) Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14(2):219\u2013225","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"5123_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/01.CIR.0000121736.16643.11","volume":"109","author":"SD Corley","year":"2004","unstructured":"Corley\u00a0SD et al (2004) Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 109(12):1509\u20131513","journal-title":"Circulation"},{"issue":"4","key":"5123_CR11","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1002\/ehf2.13407","volume":"8","author":"M D\u00f6rr","year":"2021","unstructured":"D\u00f6rr\u00a0M et\u00a0al (2021) Hospitalizations for heart failure: still major differences between East and West Germany 30\u00a0years after reunification. ESC Heart Fail 8(4):2546\u20132555","journal-title":"ESC Heart Fail"},{"issue":"10","key":"5123_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay\u00a0SM, Roger\u00a0VL, Redfield\u00a0MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14(10):591\u2013602","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"5123_CR13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.amjcard.2013.12.031","volume":"113","author":"MJ Haykowsky","year":"2014","unstructured":"Haykowsky\u00a0MJ et\u00a0al (2014) Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol 113(7):1211\u20131216","journal-title":"Am J Cardiol"},{"issue":"1","key":"5123_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11892-009-0014-9","volume":"9","author":"L van Heerebeek","year":"2009","unstructured":"van Heerebeek\u00a0L, Somsen\u00a0A, Paulus\u00a0WJ (2009) The failing diabetic heart: focus on diastolic left ventricular dysfunction. Curr Diab Rep 9(1):79\u201386","journal-title":"Curr Diab Rep"},{"issue":"5","key":"5123_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks\u00a0G et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart\u00a0J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"25 Pt A","key":"5123_CR16","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","volume":"63","author":"SJ Hwang","year":"2014","unstructured":"Hwang\u00a0SJ, Melenovsky\u00a0V, Borlaug\u00a0BA (2014) Implications of coronary artery disease in heart failure with preserved ejection fraction. J\u00a0Am Coll Cardiol 63(25 Pt A):2817\u20132827","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5123_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ejhf.1202","volume":"20","author":"A Iorio","year":"2018","unstructured":"Iorio\u00a0A et al (2018) Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a\u00a0community-based study. Eur J Heart Fail 20(9):1257\u20131266","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"5123_CR18","first-page":"297","volume":"18","author":"S Javed","year":"2021","unstructured":"Javed\u00a0S et\u00a0al (2021) Catheter ablation for atrial fibrillation in heart failure: untying the Gordian knot. J\u00a0Geriatr Cardiol 18(4):297\u2013306","journal-title":"J Geriatr Cardiol"},{"issue":"14","key":"5123_CR19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof\u00a0P et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N\u00a0Engl J Med 383(14):1305\u20131316","journal-title":"N Engl J Med"},{"issue":"20","key":"5123_CR20","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.jacc.2016.08.048","volume":"68","author":"D Kotecha","year":"2016","unstructured":"Kotecha\u00a0D et\u00a0al (2016) Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J\u00a0Am Coll Cardiol 68(20):2217\u20132228","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5123_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald\u00a0MR et\u00a0al (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart\u00a0J 29(11):1377\u20131385","journal-title":"Eur Heart J"},{"issue":"5","key":"5123_CR22","first-page":"492","volume":"379","author":"NF Marrouche","year":"2018","unstructured":"Marrouche\u00a0NF, Kheirkhahan\u00a0M, Brachmann\u00a0J (2018) Catheter ablation for atrial fibrillation with heart failure. N\u00a0Engl J Med 379(5):492","journal-title":"N Engl J Med"},{"issue":"48","key":"5123_CR23","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1093\/eurheartj\/ehab670","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA et\u00a0al (2021) Corrigendum to: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J 42(48):4901","journal-title":"Eur Heart J"},{"issue":"1","key":"5123_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh\u00a0TA et\u00a0al (2022) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4\u2013131","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"5123_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd\u00a0A, Hoes\u00a0AW (2007) Clinical epidemiology of heart failure. Heart 93(9):1137\u20131146","journal-title":"Heart"},{"issue":"3","key":"5123_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan\u00a0TE et\u00a0al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N\u00a0Engl J Med 355(3):251\u2013259","journal-title":"N Engl J Med"},{"issue":"14","key":"5123_CR27","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","volume":"143","author":"DL Packer","year":"2021","unstructured":"Packer\u00a0DL et\u00a0al (2021) Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 143(14):1377\u20131390","journal-title":"Circulation"},{"issue":"6","key":"5123_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2009.06.067","volume":"55","author":"WJ Paulus","year":"2010","unstructured":"Paulus\u00a0WJ, van Ballegoij\u00a0JJ (2010) Treatment of heart failure with normal ejection fraction: an inconvenient truth! J\u00a0Am Coll Cardiol 55(6):526\u2013537","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5123_CR29","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer\u00a0MA, Shah\u00a0AM, Borlaug\u00a0BA (2019) Heart failure with preserved ejection fraction in perspective. Circ Res 124(11):1598\u20131617","journal-title":"Circ Res"},{"issue":"12","key":"5123_CR30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.recesp.2016.10.014","volume":"69","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P et\u00a0al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed) 69(12):1167","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"5","key":"5123_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/CIRCULATIONAHA.117.030093","volume":"137","author":"YNV Reddy","year":"2018","unstructured":"Reddy\u00a0YNV et\u00a0al (2018) High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea. Circulation 137(5):534\u2013535","journal-title":"Circulation"},{"issue":"11","key":"5123_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ajh\/hpu142","volume":"27","author":"B Rodriguez-Iturbe","year":"2014","unstructured":"Rodriguez-Iturbe\u00a0B et al (2014) The immunological basis of hypertension. Am J Hypertens 27(11):1327\u20131337","journal-title":"Am J Hypertens"},{"issue":"24","key":"5123_CR33","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2020.10.022","volume":"76","author":"G Rossitto","year":"2020","unstructured":"Rossitto\u00a0G et\u00a0al (2020) Reduced lymphatic reserve in heart failure with preserved ejection fraction. J\u00a0Am Coll Cardiol 76(24):2817\u20132829","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5123_CR34","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/ejhf.142","volume":"16","author":"D Rusinaru","year":"2014","unstructured":"Rusinaru\u00a0D et al (2014) Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail 16(9):967\u2013976","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"5123_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah\u00a0SJ et al (2016) Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 134(1):73\u201390","journal-title":"Circulation"},{"issue":"37","key":"5123_CR36","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","volume":"39","author":"SJ Shah","year":"2018","unstructured":"Shah\u00a0SJ et al (2018) Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart\u00a0J 39(37):3439\u20133450","journal-title":"Eur Heart J"},{"issue":"7","key":"5123_CR37","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.2249","volume":"23","author":"SD Solomon","year":"2021","unstructured":"Solomon\u00a0SD et\u00a0al (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 23(7):1217\u20131225","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"5123_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","volume":"10","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD et\u00a0al (2022) Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail 10(3):184\u2013197","journal-title":"JACC Heart Fail"},{"issue":"5","key":"5123_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ejhf.2122","volume":"23","author":"H Sugumar","year":"2021","unstructured":"Sugumar\u00a0H et al (2021) A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF. Eur J Heart Fail 23(5):785\u2013796","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"5123_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","volume":"18","author":"JM Ter Maaten","year":"2016","unstructured":"Ter Maaten\u00a0JM et\u00a0al (2016) Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18(6):588\u2013598","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"5123_CR41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ejhf.600","volume":"18","author":"F Triposkiadis","year":"2016","unstructured":"Triposkiadis\u00a0F et al (2016) Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 18(7):744\u2013758","journal-title":"Eur J Heart Fail"},{"key":"5123_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2018.04.031","volume":"263","author":"T Tsujimoto","year":"2018","unstructured":"Tsujimoto\u00a0T, Kajio\u00a0H (2018) Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction. Int J Cardiol 263:69\u201374","journal-title":"Int J Cardiol"},{"issue":"1","key":"5123_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","volume":"11","author":"RS Vasan","year":"2018","unstructured":"Vasan\u00a0RS et\u00a0al (2018) Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging 11(1):1\u201311","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"5123_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/ehf2.13703","volume":"9","author":"SM Werhahn","year":"2022","unstructured":"Werhahn\u00a0SM et al (2022) NT-proBNP as a\u00a0marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Fail 9(1):100\u2013109","journal-title":"ESC Heart Fail"},{"issue":"46","key":"5123_CR45","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1093\/eurheartj\/ehz782","volume":"40","author":"S Willems","year":"2019","unstructured":"Willems\u00a0S et\u00a0al (2019) Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. Eur Heart\u00a0J 40(46):3793\u20133799c","journal-title":"Eur Heart J"},{"issue":"8","key":"5123_CR46","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/europace\/euaa420","volume":"23","author":"R Yamauchi","year":"2021","unstructured":"Yamauchi\u00a0R et al (2021) Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B\u2011type natriuretic peptide. Europace 23(8):1252\u20131261","journal-title":"Europace"},{"issue":"16","key":"5123_CR47","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy\u00a0CW et\u00a0al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a\u00a0report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J\u00a0Am Coll Cardiol 62(16):e147\u2013e239","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"5123_CR48","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","volume":"128","author":"R Zakeri","year":"2013","unstructured":"Zakeri\u00a0R et al (2013) Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a\u00a0community-based study. Circulation 128(10):1085\u20131093","journal-title":"Circulation"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05123-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T23:03:02Z","timestamp":1668380582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05123-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["5123"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05123-9","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"11 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.\u00a0Deichl, R.\u00a0Wachter and F.\u00a0Edelmann declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}